Skip to content

Comparison of Sevoflurane and Isoflurane Anesthesia for Benign Breast Tumor Excision

Anesthesia With Sevoflurane and Isoflurane for Excision Surgeries in Benign Breast Tumors

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00575354
Acronym
CSIABTEC
Enrollment
500
Registered
2007-12-18
Start date
2007-03-31
Completion date
2007-12-31
Last updated
2008-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Neoplasms

Keywords

Sevoflurane, Isoflurane, Breast tumor, Anesthesia

Brief summary

Generally, benign breast tumors are excised under the local anesthesia. But such action was so invasive that every patient would experience the physiological and psychological stimuli unavoidably. Sevoflurane was advised as a better inhalational anesthesic for its easy come,easy go property during short-lasting operations than isoflurane. We purposed that sevoflurane would be a superior anesthesic for benign breast tumor excision than isoflurane with relative less alteration in hemodynamics, less postoperative side effects and easily-control the depth of anesthesia.

Interventions

DRUGSevoflurane

3-6% sevoflurane inhaled for anesthesia induction, and 2-3% sevoflurane was used to maintain the anesthesia till the end of the operation.

DRUGIsoflurane

3-6% isoflurane inhaled for anesthesia induction, and 2-3% isoflurane was used to maintain the anesthesia till the end of the operation.

Sponsors

Nanjing Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

* Chinese * Diagnosed benign breast tumor patients * 18-64 yrs

Exclusion criteria

* Allergic to any interventional drugs * Organic dysfunction * Long-lasting PACU staying

Design outcomes

Primary

MeasureTime frame
Time of induction, maintenance and resuscitation0h to the end of the operation

Secondary

MeasureTime frame
Intraoperative hemodynamics; Postoperative side effects;0h to 24h after the end of the operation

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026